๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University201 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School89 Nanjing First Hospital, Nanjing Medical University68 The Second Hospital of Nanjing Medical University32 Nanjing Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanjing

1193 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China
NCT05597709Type 2 Diabetes Mellitus in Remission, Metabolic Associated Fatty Liver Disease
Wuxi Hisky Medical Technology Co Ltd
Observational
2,900
Nanjing
2022-07-01
By invitation
Clinical Study on the Integration of Traditional Chinese Medicine Virtual Hanging Therapy With Mesenchymal Stem Cells for the Treatment of Crohn's Disease-Associated Anal Fistula.
NCT07113795Crohn's Disease With Perianal Fistulas
The Anorectal Center of Nanjing Hospital of Traditional Chinese Medicine
Phase EARLY_PHASE1
90
Nanjing
2022-07-01
Recruiting
The Jinling Cohort
NCT06011694Cancer, Multi Cancer Early Screening, Liquid Biopsy
Nanjing Shihejiyin Technology, Inc.
Observational
15,000
Nanjing
2022-06-15
Active, closed
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naรฏve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT05047250Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Active, closed
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT05347134Triple Negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
254
Beijing, Nanjing
2022-06-10
Recruiting
Surgery vs Biologics for Treating Stricturing CD--a RCT
NCT05421455Crohn Disease
Zhu Weiming
Not applicable
138
Nanjing
2022-06-09
Recruiting
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
NCT05766449Chronic Hepatitis b, Non-alcoholic Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
1,000
Nanjing
2022-06-01
Not yet open
A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
NCT05343377Extranodal Natural Killer/T-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Not applicable
72
Nanjing
2022-06-01
Recruiting
A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors
NCT05217693Solid Tumor
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase 1
288
Beijing, Changsha, Ganzhou, Hangzhou, Hanzhou, Linyi, Nanjing
2022-06-01
Recruiting
Evaluation of Clinical Outcomes of Unruptured bAVMs Treated With Medical Management Alone Based on Multimodal CT
NCT05449106Brain Arteriovenous Malformations
Beijing Tiantan Hospital
Observational
200
Beijing, Zhengzhou, Nanjing
2022-05-25
Recruiting
Different Treatment Strategies on Prognosis of Acute Ischemic Stroke(AISDTS)
NCT05410457Ischemic Stroke
Nanjing First Hospital, Nanjing Medical University
Observational
5,000
Nanjing
2022-05-24
Recruiting
Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome
NCT05397405Intracranial Artery Stenosis
Nanjing First Hospital, Nanjing Medical University
Not applicable
180
Nanjing
2022-05-23
Active, closed
A Study of AL8326 in Non-Small Cell Lung Cancer
NCT06794957Non-small Cell Lung Cancer
Advenchen Laboratories, LLC
Phase 1
158
Bengbu, Hefei, Xuancheng, Anyang, Zhengzhou, Wuhan, Nanjing, Hangzhou
2022-05-19
Recruiting
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
NCT05179876Hypertension, Pulmonary
Actelion
Phase 3
280
Beijing, Changsha, Nanjing, Qingdao, Shanghai, Xi'an
2022-05-04
Recruiting
Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
NCT05887661Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2022-05-01
Recruiting
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
NCT06417502Autoimmune Diseases, Autoinflammatory Diseases
Peking Union Medical College Hospital
Observational
20,000
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Hangzhou
2022-04-29
By invitation
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
NCT05303532Cancer
AstraZeneca
Phase 3
214
Beijing, Changsha, Hangzhou, Nanjing, Shanghai, Shenyang, Wenzhou, Xi'an
2022-04-19
Recruiting
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
NCT05758389Head and Neck Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
29
Nanjing
2022-04-01
Not yet open
The Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy
NCT05356156Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
1,968
Nanjing
2022-04
Not yet open
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
NCT05181501Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
20
Hefei, Changzhou, Nanjing
2022-04
Recruiting
National Registry and Cohort Study of Pulmonary Vascular Disease
NCT05368467Pulmonary Arterial Hypertension
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Guangzhou, Nanjing, Tianjin, Beijing, Changsha, Chendu, Shenyang, Wuhan
2022-03-29
Active, closed
STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation
NCT05352074Slow Transit Constipation, Surgery
Third Military Medical University
Not applicable
252
Yuzhong, Lanzhou, Wuhan, Nanjing, Shengyang, Qingdao, Pudong, Xiโ€™an
2022-03-27
Recruiting
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
NCT05494060Carcinoma, Gastrointestinal Diseases, Stomach Cancer, Gastroesophageal-junction Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
80
Nanjing
2022-03-16
Recruiting
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
NCT05553093Type 2 Diabetes Mellitus
Nanjing First Hospital, Nanjing Medical University
Phase 4
150
Nanjing
2022-03-15
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Recruiting
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
NCT05584761Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University
Phase 1/2
50
Nanjing
2022-03-01
Active, closed
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
Allist Pharmaceuticals, Inc.
Phase 1/2
48
Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2022-02-17
Active, closed
Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning
NCT06798142Toxic Encephalopathy, Diquat Poisoning
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
193
Nanjing
2022-02-01
Recruiting
Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy
NCT05830136Hepatic Ischemia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2022-02-01
Active, closed
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
NCT05353816End-stage Heart Failure
Shenzhen Core Medical Technology CO.,LTD.
Not applicable
50
Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou
2022-01-26
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Recruiting
Whole Body MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Radiographic axSpA and Non-radiographic axSpA
NCT07230327Spondyloarthritis (SpA), Whole-body MRI (WBMRI)
The First Affiliated Hospital with Nanjing Medical University
Observational
100
Nanjing
2022-01-01
Recruiting
An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors
NCT05166070Solid Tumor
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
24
Nanjing
2022-01-01
Recruiting
China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
NCT05498974Type1diabetes, Diabetes
Second Xiangya Hospital of Central South University
Observational
20,000
Lanzhou, Shenzhen, Haikou, Harbin, Luoyang, Changsha, Nanjing, Changzhi
2022-01-01
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Recruiting
Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death
NCT06856993Sudden Cardiac Death, Exosome Multiomics, Clinical Prognosis
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
300
Nanjing
2021-12-22
Active, closed
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287Asthma
Sanofi
Phase 4
1,339
Beijing, Dongguan, Guangzhou, Guiyang, Hebei, Hefei, Nanchang, Nanjing
2021-12-16
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,007
Wuhan, Nanjing, Yinchuan, Taiyuan, Hangzhou, Wenzhou, Beijing, Shanghai
2021-12-13
Recruiting
Corheart 6: Long-term Cohort Study
NCT07094919Heart Failure
China National Center for Cardiovascular Diseases
Not applicable
160
Shenzhen, Zhengzhou, Wuhan, Nanjing, Beijing, Shanghai
2021-12-12
Active, closed
TACS Intervention for Methamphetamine Addiction
NCT06288997Methamphetamine Use Disorder
Shanghai Mental Health Center
Not applicable
70
Beijing, Wuhan, Nanjing, Suzhou, Deyang
2021-11-21
Active, closed
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
NCT04940052Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals
Phase 3
153
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu
2021-11-15
Recruiting
Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer
NCT05508126Gastric Cancer Stage
The First Affiliated Hospital with Nanjing Medical University
Observational
222
Nanjing
2021-11-01
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
Hoffmann-La Roche
Phase 3
478
Beijing, Changchun, Guangzhou, Harbin, Nanchang, Nanjing, Shanghai, Tianjin
2021-10-27
Recruiting
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Bayer
Phase 1/2
400
Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan
2021-10-25
Active, closed
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
NCT05030506Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Phase 1
45
Beijing, Guangzhou, Nanjing, Tianjin, Hangzhou
2021-10-13
Active, closed
Study of Sacituzumab Govitecan in Patients With Solid Tumor
NCT05119907Solid Tumor
Gilead Sciences
Phase 2
53
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing
2021-10-12
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
Novartis Pharmaceuticals
Phase 3
405
Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Suzhou, Xian, Chengdu
2021-10-06
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Recruiting
Performances on Cognitive Functions and Brain Function and Follow-up After Different Treatments in Patients With Autonomous Cortisol Secretion: a Single-center, Prospective, Observational Study
NCT05357456Autonomous Cortisol Secretion, Adrenal Incidentaloma, Non-functioning Adrenal Adenomas
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
62
Nanjing
2021-10-01
Recruiting
Total Meso-rectal Excision Versus Transanal Local Excision Followed by Radiotherapy for T2N0M0 Distal Rectal Cancer
NCT04098471Rectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
168
Nanjing
2021-10-01
Active, closed
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
NCT05129904DPMAS Therapy in Liver Disease Patients
Nanfang Hospital, Southern Medical University
Observational
1,300
Chongqing, Guangzhou, Hebei, Changsha, Nanjing, Xuzhou, Nanchang, Changchun
2021-09-15
Recruiting
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT04986423Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
Phase 2
200
Hefei, Chongqing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Shenyang
2021-09-08
Active, closed
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
Wenjun Cheng
Phase 2
56
Huai'an, Nanjing, Suzhou, Wuxi, Yancheng
2021-08-24
By invitation
Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
NCT06101940Myotonic Dystrophy 1
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
Active, closed
A Phase โ…ข Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
NCT04914598Malignant Pleural Effusion
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
290
Nanjing
2021-07-28
Active, closed
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT06868654Multiple Myeloma
GlaxoSmithKline
Phase 3
72
Beijing, Changchun, Guangzhou, Hangzhou, Jinan, Nanjing, Shenyang, Suzhou
2021-07-28
Recruiting
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer โ‰ค 2 cm in the Middle Third of the Lung Field
NCT04944563Lung Neoplasms, Surgery
The First Affiliated Hospital with Nanjing Medical University
Not applicable
1,120
Nanjing
2021-07-20
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naรฏve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFฮฑ Inhibitor Treatment
NCT04908189Psoriatic Arthritis
Bristol-Myers Squibb
Phase 3
729
Bengbu, Beijing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Changzhou, Nanjing
2021-07-15
Active, closed
PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale BREAST Cancers, PERCEIVE-BREAST
NCT06979921Cancer
The First Affiliated Hospital with Nanjing Medical University
Observational
496
Nanjing, Qingdao
2021-07-10
Recruiting
Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
NCT05123625Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2021-07-01
Recruiting
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
NCT05775419Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, Side Effect of Drug
The First Affiliated Hospital with Nanjing Medical University
Not applicable
1,216
Nanjing
2021-06-30
Active, closed
Protection of Cardiac Function With Left Bundle Branch Pacing in Patients With Atrioventricular Block
NCT04624763Atrioventricular Block
The First Affiliated Hospital with Nanjing Medical University
Not applicable
683
Nanjing
2021-06-22
Active, closed
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
NCT04720157Prostatic Neoplasms
Novartis Pharmaceuticals
Phase 3
1,140
Nanjing, Xian, Chengdu, Beijing, Guangzhou, Shanghai, Tianjin
2021-06-09
Active, closed
Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase โ…ข Clinical Study
NCT07306663Esophageal Cancer
Jiangsu Cancer Institute & Hospital
Phase 3
242
Nanjing
2021-06-01
Recruiting
Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism
NCT04922892Secondary Hyperparathyroidism;Parathyroidectomy
The Second Hospital of Nanjing Medical University
Not applicable
200
Nanjing
2021-06-01
Recruiting
Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation
NCT04864145Aortic Valve Disease
Nanjing First Hospital, Nanjing Medical University
Not applicable
210
Nanjing
2021-05-21
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
Janssen Research & Development, LLC
Phase 1/2
420
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing
2021-05-19
Active, closed
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
NCT04821622Prostate Cancer
Pfizer
Phase 3
599
Hefei, Beijing, Lanzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2021-05-12
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Active, closed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344Muscle-invasive Bladder Cancer
Hoffmann-La Roche
Phase 3
761
Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2021-05-03
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 3
557
Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin
2021-04-26
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
808
Guangzhou, Changsha, Nanjing, Nantong, Shanghai
2021-04-21
Active, closed
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
NCT04765657Hypercholesterolemia
Novartis Pharmaceuticals
Phase 3
345
Lanzhou, Foshan, Guangzhou, Shijiazhuang, Baotou, Hohhot, Nanjing, Nantong
2021-03-01
Recruiting
The Study of Electrical Acupuncture Stimulation Therapy for Postprostatectomy Incontinence
NCT04972669Postprostatectomy Incontinence
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
110
Nanjing
2021-03-01
Active, closed
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Celgene
Phase 3
313
Guangzhou, Nanyang, Changsha, Nanjing, Nantong, Nanchang, Qingdao, Taiyuan
2021-02-25
Recruiting
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
NCT04532606Benzodiazepines, Bladder Cancer, Delirium, Surgery
Peking University First Hospital
Phase 4
1,128
Beijing, Beijin, Guiyang, Nanjing, Shanghai
2021-02-05
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Recruiting
Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)
NCT04444349Cardiovascular Disease
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu
2021-02-01
Recruiting
Washed Microbiota Transplantation for the Treatment of Oncotherapy-Related Intestinal Complications
NCT04721041Intestinal Complications, Cancer
The Second Hospital of Nanjing Medical University
Not applicable
200
Nanjing
2021-01-26
Active, closed
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
NCT04544189Breast Neoplasms
Novartis Pharmaceuticals
Phase 2
69
Hefei, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing
2021-01-20
Active, closed
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
NCT04718883Mantle Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Active, closed
Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC
NCT06557187Brain Metastases, Non-small Cell Lung Cancer
Yatian Liu
Not applicable
40
Nanjing
2021-01-01
Recruiting
Biologics for Stricturing Crohn's Diseases
NCT05645055The Efficacy of Biologics for Stricturing Crohn's Diseases
Jinling Hospital, China
Observational
200
Nanjing
2021-01-01
Recruiting
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
NCT05800054Esophageal Neoplasms, Adverse Drug Event
The First Affiliated Hospital with Nanjing Medical University
Not applicable
210
Nanjing
2021-01-01
Recruiting
Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)
NCT04699279Acute Aortic Syndrome, Aortopathy
Nanjing Medical University
Not applicable
300
Guangzhou, Nanjing, Qingdao, Chengdu, Beijing
2021-01-01
Active, closed
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
NCT04666272Melanoma
Novartis Pharmaceuticals
Observational
78
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing
2020-12-31
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
605
Beijing, Changsha, Hangzhou, Hangzou, Heilongjiang, Henan, Hubei, Nanjing
2020-12-21
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
Pfizer
Phase 3
841
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing
2020-12-21
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Dongguan, Fuzhou, Baotou, Nanjing, Nantong, Shanghai, Chengdu, รœrรผmqi
2020-12-11
Recruiting
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
NCT04595864Hepatocellular Carcinoma, Liver Transplantation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
40
Nanjing
2020-11-01
Active, closed
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
NCT07204327Unresectable Hepatocellular Carcinoma
Zhongda Hospital
Observational
1,136
Nanjing
2020-10-28
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Phase 3
210
Beijing, Guangzhou, Hangzhou, Nanjing, Nantong, Shanghai, Wuhan
2020-10-08
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
696
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2020-09-23
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Active, closed
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions
NCT04242134Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Not applicable
784
Nanjing
2020-09-08
Active, closed
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT04537156Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata
Xiamen University
Phase 3
9,327
Nanjing, Chengdu
2020-09-05
Rows per page Showing 1001–1100 of 1193
Previous 9 10 11 12 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing?page=11

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,193 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

713 of the 1,193 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 232 have not yet opened recruitment, 216 are active but closed to new participants, and 32 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.